-
Is the recent BMS-Nektar NKTR-214 deal really the most lucrative agreement in biotech history?
Bristol-Myers Squibb (BMS) and Nektar Therapeutics (Nektar) have agreed to a Global Development & Commercialisation Collaboration, to work on Nektar’s lead oncology program, the CD122-biased agonist, NKTR-214. We assess who we think got the best out of this deal!
